Attached files

file filename
EX-32.2 - CERTIFICATION - PLURISTEM THERAPEUTICS INCf10q0920ex32-2_pluristem.htm
EX-31.2 - CERTIFICATION - PLURISTEM THERAPEUTICS INCf10q0920ex31-2_pluristem.htm
EX-31.1 - CERTIFICATION - PLURISTEM THERAPEUTICS INCf10q0920ex31-1_pluristem.htm
EX-10.2 - GUARANTEE AGREEMENT BY AND AMONG THE EUROPEAN INVESTMENT BANK, PLURISTEM LTD. AN - PLURISTEM THERAPEUTICS INCf10q0920ex10-2_pluristem.htm
EX-10.1 - GUARANTEE AGREEMENT BY AND AMONG THE EUROPEAN INVESTMENT BANK, PLURISTEM THERAPE - PLURISTEM THERAPEUTICS INCf10q0920ex10-1_pluristem.htm
10-Q - QUARTERLY REPORT - PLURISTEM THERAPEUTICS INCf10q0920_pluristem.htm

Exhibit 32.1

 

CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350

 

In connection with the Quarterly Report (the “Report”) of Pluristem Therapeutics Inc. (the “Company”) on Form 10-Q for the period ended September 30, 2020, as filed with the Securities and Exchange Commission on the date hereof, I, Yaky Yanay, Chief Executive Officer and President of the Company, certify, pursuant to 18 U.S.C. 1350, that to my knowledge:

 

1.The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

 

2.The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

 

Date: November 5, 2020  
  By: /s/ Yaky Yanay
    Yaky Yanay
    Chief Executive Officer and President